Gastrointestinal Discomfort: In some cases, individuals using BPC-157 may experience mild gastrointestinal discomfort, such as bloating, nausea, or abdominal pain
Peptide Vials (NAD+, 500 mg each) 8 weeks: Approximately 11 vials (total ~5,075 mg used) 12 weeks: Approximately 16 vials (total ~7,875 mg used) 16 weeks: Approximately 22 vials (total ~10,675 mg used) Insulin Syringes (U-100, 1 mL) Weekly usage: 7 syringes (one per day) 8 weeks: 56 syringes 12 weeks: 84 syringes 16 weeks: 112 syringes Bacteriostatic Water (10 mL bottles) Each vial requires 3.0 mL for proper reconstitution
Outside of clinical studies, to investigate the potential roles of pCBs for the treatment and alleviation of skin diseases and disorders, many types of cell lines have been used in various in vitro studies: inflamed human keratinocytes (HaCaT cells) [29], human SZ95 sebocytes [30], human eccrine-sweat-gland-derived immortalized NCL-SG3 model cells [31], human healthy and stress-induced premature senescent (SIPS) CCD-1064Sk dermal fibroblasts [32], or My-La and HuT-78 cutaneous T-cell lymphoma lines [33]
doi: 10.1016/j.biocel.2014.05.016
Combination of the GLUT4 inhibitor ritonavir with the complex I inhibitor metformin, which increases dependence on glycolytic ATP production, has been shown to overcome ritonavir resistance and effectively elicit cell apoptosis in both in vivo and vitro studies of MM (103)
